Explore Business Standard
Dr Reddy's Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire Stugeron brand across the EMEA regions, with India and Vietnam as key markets. Stugeron contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. The acquisition presents a strategic opportunity for the Hyderabad-based drug firm to expand its footprint in the anti-vertigo space as well as strengthen its Central Nervous System (CNS) portfolio, Dr Reddy's Laboratories said in a statement. Dr Reddy's acquisition of the brand reflects a steady advancement in the company's efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of CNS portfolio, said MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories. "Backed by our strong market access, we intend to extend the reach of Stugeron and its associated products across 18 key markets in the ..
A US bankruptcy court judge has denied Johnson & Johnson's settlement plan related to baby powder containing talc, providing another setback in the company's efforts to resolve the matter. This is the third bankruptcy case for a J&J company as it relates to the baby powder issue. Red River Talc LLC, a J&J subsidiary, was seeking confirmation of a proposed prepackaged Chapter 11 bankruptcy plan that would have been one of the biggest mass tort settlements in history, if approved. Red River and J&J proposed to pay USD 9 billion to settle ovarian cancer and other gynecological cancer litigation claims based on talc-related products. But Judge Christopher Lopez of the US Bankruptcy Court for the Southern District of Texas, Houston division said in a court filing that J&J used a faulty voter solicitation process when dealing with personal injury claimants. J&J said in a statement that it will not pursue an appeal, and instead will return to the civil law system to ..
Johnson and Johnson, US healthcare's leading, most comprehensive innovation powerhouse, announced on Friday that it will invest more than USD 55 billion in manufacturing, research and development, and technology in the United States over the next four years.According to Johnson and Johnson's statement, this represents a 25 per cent increase in investment compared to the previous four years and builds upon the Company's already elevated US investment levels resulting from the passage of the 2017 Tax Cuts & Jobs Act."Today's announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world's toughest healthcare challenges," said Joaquin Duato, Chairman and Chief Executive Officer of Johnson and Johnson. "Our increased US investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add US-based jobs but manufacture cutting-edge medicines to treat patients in America and around the world."In addition to